Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib PK in Hepatic Impairment
NCT02300025Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cobimetinib in melanoma (4 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Plasma Concentration at 576 hours, Time to Reach Maximum Observed Plasma Concentration at 576 hours and 7 more. Started Aug 2014; status: completed.
02
Drugs
cobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02300025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300025.